IMVT in the 13F filings
Immunovant Inc · CUSIP 45258J102
- Quarter end
- 31 Dec 2024
- the date the book describes
- Filed
- 14 Feb 2025
- latest of these filings; the earliest 13 Feb 2025
- Managers listing it
- 3
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q3 2024 and Q4 2024; 3 listed it in both
- Shares listed
- 2,062,016
- combined, among listed positions
- Reported value
- $51m
- combined, at the quarter end
Among the 94 comparable managers: 0 buyers (opened or added shares) and 3 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -2,662,100.
Managers listing IMVT in Q4 2024
3 of 3 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Viking Global Investors LP | 1,407,290 | $35m | 0.11% | Trimmed | -913,612 | 14 Feb 2025 (the filing on sec.gov) |
| Woodline Partners LP | 642,726 | $16m | 0.11% | Trimmed | -772,251 | 14 Feb 2025 (the filing on sec.gov) |
| Farallon Capital Management LLC | 12,000 | $297k | under 0.1% | Held | 0 | 14 Feb 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
No increase among listed positions.
Reductions
- Viking Global Investors LPexisting position · 1,407,290 shares now-913,612
- Woodline Partners LPexisting position · 642,726 shares now-772,251
New positions and exits
New (0)
No new position among listed positions.
Exited (1)
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2019 | 2 | $5.7m | n.a. | n.a. |
| Q1 2020 | 1 | $5.1m | n.a. | n.a. |
| Q2 2020 | 1 | $5.6m | n.a. | n.a. |
| Q3 2020 | 3 | $60m | n.a. | n.a. |
| Q4 2020 | 3 | $34m | n.a. | n.a. |
| Q1 2021 | 3 | $22m | n.a. | n.a. |
| Q2 2021 | 2 | $41m | n.a. | n.a. |
| Q3 2021 | 1 | $2.1m | n.a. | n.a. |
| Q4 2021 | 1 | $930k | n.a. | n.a. |
| Q1 2022 | 1 | $745k | n.a. | n.a. |
| Q3 2022 | 2 | $21m | n.a. | n.a. |
| Q4 2022 | 2 | $24m | n.a. | n.a. |
| Q1 2023 | 3 | $30m | n.a. | n.a. |
| Q2 2023 | 3 | $49m | n.a. | n.a. |
| Q3 2023 | 5 | $111m | n.a. | n.a. |
| Q4 2023 | 5 | $205m | 3 | 2 |
| Q1 2024 | 4 | $176m | 2 | 3 |
| Q2 2024 | 5 | $136m | 4 | 0 |
| Q3 2024 | 4 | $135m | 0 | 1 |
| Q4 2024 | 3 | $51m | 0 | 3 |
| Q1 2025 | 3 | $45m | 1 | 1 |
| Q2 2025 | 4 | $81m | 3 | 1 |
| Q3 2025 | 3 | $80m | 1 | 0 |
| Q4 2025 | 3 | $101m | 11 | 12 |
| Q1 2026 | 3 | $90m | 12 | 9 |
| Q2 2026 | 4 | $927m | 15 | 8 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
IMVT and GILD →IMVT and AMGN →IMVT and ARGX →Choose a stock to compare with IMVT →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own IMVT, latest filings →Back to the 13F Explorer →